Aug 11, 2025
Our SXSW 2026 panel will explore how psychedelics, cannabis, and policy reform could transform addiction treatment. Featuring cannabis and psychedelics lawyer Shawn Hauser, pioneering researcher Dr. Sue Sisley, and SXSW-winning filmmaker Justin Benoliel. Vote for “Can Psychedelics Change How We Treat Addiction?” by August 24 to help bring this important conversation to the stage.
May 23, 2024
Watch this session hosted by Vicente’s Psychedelics & Emerging Therapies team. We dive into the rules and discuss what you need to know to be prepared to participate in Colorado's Natural Medicine program launching on January 1, 2025!
May 14, 2024
Join Vicente LLP attorneys at the 2024 Aspen Psychedelic Symposium for a weekend of panels, groundbreaking research, and firsthand insights into the transformative world of psychedelic medicines. This two-day gathering, sponsored by Vicente, will take place in Aspen, Colorado, from May 31 to June 1. Register now!
Apr 5, 2024
Vicente LLP founding partner Joshua Kappel and counsel Barine Majewska will be at the upcoming “Cultivating Roots for Cultural Change: the Bay Area’s Annual Spring Conference on Plant Medicines & Psychedelic Science.” Hosted by Chacruna, the event will take place on April 27 and 28, 2024, at the historical Brava Theater Center in San Francisco, California.
Apr 5, 2024
On April 18, 2024, Vicente LLP attorneys Joshua Kappel and Barine Majewska will attend the “Bridging the Worlds: The Confluence of Indigenous Wisdom and Psychedelic Science” conference at the University of Colorado Anschutz Medical Campus in Aurora, CO. Vicente is a sponsor of the event, which will explore the future of psychedelic research in the context of its historical and cultural significance.
Mar 28, 2024
Watch this pre-recorded session to learn about the future of intellectual property for cannabis and hemp products with rescheduling on the horizon. This webinar will feature a discussion with VLLP IP specialists regarding patent, IP and trademark protection, cannabis research, and what may change with potential federal marijuana rescheduling.
Mar 15, 2024
On April 2, The Emerald Conference will feature a talk by Vicente LLP director of economics and research Andrew Livingston on how variations between the cannabis and psychedelic markets may influence research design, data collection, and overall program evaluation. Register to attend and learn more!
By Vicente LLP, Psychedelic Alpha
Mar 5, 2024
Vicente LLP provides a full breakdown of the first set of draft rules regarding Colorado's regulated psychedelics program. The thirty-nine pages of draft rules cover facilitator licensing and training programs, representing months of work by the Natural Medicine Advisory Board and state regulators.
By Joshua Kappel, Jeff Fitzgerald, Psychedelic Alpha
Feb 27, 2024
Vicente LLP shares a high-level overview of the first draft rules for Colorado's regulated natural medicine market. These draft rules focus on facilitator qualifications, education requirements, and training programs.
By Joshua Kappel, Jeff Fitzgerald, Psychedelic Alpha
Feb 15, 2024
Colorado Natural Medicine Advisory Bulletins provide updates on the implementation of Colorado's legal psychedelics program, the Natural Medicine Health Act. Bulletin #8.1 gives context to the 123 recommendations which will form the basis of the regulated nature medicine program approved by Colorado voters in November 2022.
By Joshua Kappel, Jeff Fitzgerald, Psychedelic Alpha
Feb 14, 2024
Colorado Natural Medicine Advisory Bulletins provide updates on the implementation of Colorado's legal psychedelics program, the Natural Medicine Health Act. Bulletin #8 focuses on updates on the NMAB's initial set of recommendations for the state’s regulated natural medicine program
By Joshua Kappel, Jeff Fitzgerald, Psychedelic Alpha
Jan 18, 2024
Colorado Natural Medicine Advisory Bulletins provide updates on the implementation of Colorado's legal psychedelics program, the Natural Medicine Health Act. Bulletin #7 focuses on updates from the recent subcommittee meetings.
By Jason Adelstone
Dec 7, 2023
On October 27, 2023, the Ninth Circuit Court of Appeals, in Aggarwal v. DEA, held that the U.S. Drug Enforcement Agency (DEA) must reconsider its denial of a petition to transfer psilocybin, the active ingredient in “magic mushrooms” from Schedule I to Schedule II. Read this Insights post for more information about the Ninth Circuit Court’s order to reschedule psilocybin.
Nov 29, 2023
Vicente LLP psychedelics attorneys Joshua Kappel and Shawn Hauser were selected to speak on panels focused on functional alcohol substitutes and psilocybin medicine during the Psychedelics Track at SXSW in March 2024.
Nov 10, 2023
Federal and international law and policy insights, news and events from Vicente LLP.